# Major Life Sciences Licensing Deal Trends in China in 2023

 *This is the first of two articles focused on 2023 life sciences deals in China. The second article, which is coming soon, looks at trends in M&A.*

In 2023, there were 240 reported life sciences licensing deals in China, an increase of almost 50% compared to 2021.

That includes 70 out-license deals involving Chinese companies licensing drugs and technologies to foreign companies, with a disclosed aggregate deal value surpassing US$35 billion.

It also includes 170 in-license deals involving Chinese companies licensing drugs and technologies from other Chinese companies or from foreign companies. This represents a 32% increase compared to 2021 — and a 58% increase compared to 2022 (more than making up for the 2022 dip in deals).

Read the full alert **here**.